Bone Metabolism Adjacent to Hip Prosthetic Surfaces. A Clinical F-PET/CT Study

NCT ID: NCT02320682

Last Updated: 2018-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

What is the intensity of F-PET uptake adjacent to four analyzed hip endoprosthetic components and in healthy femur and acetabulum, 1, 4 and 9 months after surgery?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A clinical study of 32 patients, age 50-69 years, healthy unless osteoarthritis in one hip, randomized in two groups (16 each) plus a reference group of same 32 patient´s contralateral healthy hip.

Intervention will be surgery with a total hip arthroplasty. The four studied endoprosthetic components are:

* Cemented Exeter stem (Stryker Warsaw, USA) with a ceramic 32 mm head and Palacose cement with gentamycin, applied with 3:rd generation cementation technique.
* Uncemented Lubinus SP-CL stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
* Uncemented Delta PF cup (Limacorporate spa, Udine, Italy).
* Uncemented fibrous metal Delta TT cup (Limacorporate spa, Udine, Italy). Both cups will have cross linked Ultra-high-molecular-weight polyethylene (UHWMP).

Clinical score, radiography and uptake of Fluoride tracer will be analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Osteo Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exeter femur component and Delta TT acetabular component

Group Type ACTIVE_COMPARATOR

Surgery for Total Hip Arthroplasty (THA)

Intervention Type DEVICE

THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.

SP-CL femur component and Delta TT acetabular component

Group Type ACTIVE_COMPARATOR

Surgery for Total Hip Arthroplasty (THA)

Intervention Type DEVICE

THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.

SP-CL femoral component and Delta PF acetabular component

Group Type ACTIVE_COMPARATOR

Surgery for Total Hip Arthroplasty (THA)

Intervention Type DEVICE

THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.

Exeter femoral component and Delta PF acetabular component

Group Type ACTIVE_COMPARATOR

Surgery for Total Hip Arthroplasty (THA)

Intervention Type DEVICE

THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surgery for Total Hip Arthroplasty (THA)

THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- patients diagnosed to have unilateral hip osteo arthritis verified by radiography (Charnley group A) aimed for THA at Gävle hospital and accepting to participate in the study.

Exclusion Criteria

* any systemic disease (other than osteo arthritis) or medication affecting skeleton methabolism
Minimum Eligible Age

50 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

gosta ullmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

gosta ullmark

Assistent Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gösta Ullmark, MD

Role: PRINCIPAL_INVESTIGATOR

Orthopaedic department Gävle hospital, Gävle, Sweden and Centre for Research & Development Uppsala University/County Council of Gävleborg.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orthopaedic department Gävle hospital

Gävle, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Sotiriou D, Sorensen J, Ullmark G. [18F]-fluoride PET/CT analyses of postoperative bone mineralisation adjacent to femoral stems at THA: a randomised clinical trial. Hip Int. 2025 Sep 30:11207000251372025. doi: 10.1177/11207000251372025. Online ahead of print.

Reference Type DERIVED
PMID: 41025388 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Fingerprint III

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.